Welcome to our dedicated page for Kazia Therapeutics American Depositary Shares news (Ticker: KZIA), a resource for investors and traders seeking the latest updates and insights on Kazia Therapeutics American Depositary Shares stock.
Kazia Therapeutics Limited (NASDAQ: KZIA) is an innovative biotechnology company focused on oncology, based in Sydney, Australia. The company is dedicated to developing cutting-edge anti-cancer drugs, with a robust pipeline aimed at addressing various forms of cancer.
The lead program for Kazia is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway. Paxalisib is primarily developed for treating glioblastoma multiforme, a highly aggressive brain cancer. Licensed from Genentech in late 2016, paxalisib has been the subject of numerous clinical trials. A Phase II study reported promising clinical activity, and the drug is currently undergoing pivotal trials, with additional studies targeting brain metastases and other central nervous system (CNS) cancers.
Besides paxalisib, Kazia is advancing EVT801, a small-molecule VEGFR3 inhibitor, licensed from Evotec SE in April 2021. EVT801 has shown preclinical efficacy across a range of tumor types and synergy with immuno-oncology agents. It's currently in Phase I clinical trials for advanced solid tumors.
Another notable drug in Kazia’s pipeline is Cantrixil (TRXE-002-1), under development for ovarian cancer and in Phase I clinical trials in Australia and the United States.
Kazia’s commitment to innovation and collaboration is evident through strategic partnerships and licensing agreements. For example, they recently signed a non-binding Letter of Intent with a biotechnology company to develop and commercialize paxalisib outside oncology, targeting epilepsy related to focal cortical dysplasia type 2 and tuberous sclerosis complex.
Financially, Kazia remains focused on securing funding to sustain its research and development endeavors. The company recently announced a direct offering expected to generate approximately $2 million.
Additionally, Kazia's forward-looking strategy includes addressing market listing requirements and ensuring compliance with Nasdaq’s Minimum Bid Price Requirement.
For more information, visit www.kaziatherapeutics.com or follow them on Twitter @KaziaTx.
Kazia Therapeutics Limited (KZIA) has commenced patient enrollment for a Phase I clinical trial of EVT801, an investigational cancer therapy. Licensed from Evotec SE in April 2021, EVT801 targets VEGFR3 to inhibit lymphangiogenesis, showing promising preclinical results. The trial aims to assess safety, tolerability, and pharmacokinetics while exploring preliminary efficacy signals through biomarker analyses. The study will recruit up to 60 patients at the IUCT-Oncopole in Toulouse, France, focusing on renal cell carcinoma and soft-tissue sarcoma. Kazia anticipates further updates as the trial progresses.
Kazia Therapeutics anticipates releasing critical data from its paxalisib program in Q4 2021, including results from a 30-patient Phase II trial for newly diagnosed glioblastoma multiforme and initial data for treating brain metastases. The company has raised its valuation to US$277 million or US$20.92 per basic ADR, which reflects a forward adjustment in its NPV, despite lower net cash of US$20.4 million as of June 30, 2021. Kazia's financing requirement has increased to US$44 million, driven by heightened R&D expenditure.
Kazia Therapeutics Limited (NASDAQ: KZIA) will present at the LD Micro Main Event from October 12-14, 2021. CEO Dr. James Garner will discuss significant developments in 2021, including three cross-border licensing deals and the start of an international pivotal study for its lead asset, paxalisib. The hybrid event will feature around 120 companies, with the Kazia presentation scheduled for 10 AM ET on October 12. Registration for the conference is complimentary and available through the conference website.
Kazia Therapeutics Limited (NASDAQ: KZIA) will present at the HC Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. CEO Dr. James Garner will discuss the company's pivotal study on paxalisib, aimed at treating glioblastoma, which affects over 12,500 patients annually. The market potential for this treatment is valued at US$ 1.5 billion. Significant developments include an out-licensing deal for pazalisib in Greater China and in-licensing of another oncology asset, EVT801. Dr. Garner will also outline Kazia's objectives for FY2022.
Kazia Therapeutics Limited (NASDAQ: KZIA) highlights Glioblastoma (GBM) Awareness Day on July 21, 2021, urging increased research focus on this aggressive brain cancer, which affects around 13,000 Americans annually. Current GBM treatments yield limited benefits, with median survival at 16 months. CEO Dr. James Garner expresses confidence in future treatment advancements, particularly with the drug paxalisib, currently in phase II trials. Kazia calls for collaboration among stakeholders to improve GBM treatment prospects.
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) provided an update on its oncology pipeline, focusing on paxalisib and EVT801. The GBM AGILE study for paxalisib is recruiting nearly 25 sites ahead of schedule in the U.S., with over 650 patients screened to date. The phase II study of paxalisib has seen its final patient complete treatment, while the phase I study of EVT801 has submitted its protocol to French regulators. Kazia anticipates upcoming data releases from ongoing studies in 2021.
Kazia Therapeutics Limited (NASDAQ: KZIA) has initiated a collaboration with Weill Cornell Medical College for a Phase II clinical trial examining paxalisib combined with a ketogenic diet for glioblastoma treatment. This study aims to explore the potential of ketogenesis in enhancing paxalisib's effectiveness and reducing side effects like hyperglycemia. Led by Dr. Howard Fine, the trial will consist of two arms, with an initial cohort of 16 patients in each. Recruitment is expected to start by the end of 2021, pending regulatory approvals.
Kazia Therapeutics Limited (NASDAQ: KZIA) has initiated a phase II clinical study of its investigational drug, paxalisib, targeting primary CNS lymphoma at the Dana-Farber Cancer Institute. The study, which has enrolled its first patient, aims to recruit a total of 25 patients over the next two years. Paxalisib is the only PI3K inhibitor capable of penetrating the blood-brain barrier, addressing a significant treatment gap for patients with CNS lymphoma. Kazia is providing support for the trial, including the study drug and financial grant.
Kazia Therapeutics Limited (NASDAQ: KZIA) announced that its CEO, Dr. James Garner, will present virtually at the LD Micro Invitational XI on June 9, 2021, at 5 PM ET. The company is advancing its lead program, paxalisib, in a pivotal study for glioblastoma and expects to begin clinical trials for a new program, EVT801, in 2021. The LD Micro Invitational runs from June 8-10, showcasing around 180 companies. Investors can register for free at the event's website.
Kazia Therapeutics has expanded its pipeline by acquiring EVT801, a small molecule inhibitor targeting VEGFR3, from Evotec for €1m upfront plus potential milestones of €308m and tiered single-digit royalties. EVT801, developed in collaboration with Sanofi, is currently in preclinical development, with a Phase I study expected to launch by the end of CY21. The company increased its valuation to US$247m or US$19.14 per basic ADR, up from US$215m. This expansion also raises Kazia's financing requirement to US$36m from US$7m, reflecting increased R&D spending.
FAQ
What is the current stock price of Kazia Therapeutics American Depositary Shares (KZIA)?
What is the market cap of Kazia Therapeutics American Depositary Shares (KZIA)?
What is Kazia Therapeutics’ primary focus?
What is paxalisib?
What stage are paxalisib’s clinical trials in?
What other drugs are in Kazia’s pipeline?
How is Kazia financing its projects?
What recent partnerships has Kazia formed?
What are the latest clinical trial developments for EVT801?
How does Kazia ensure compliance with Nasdaq’s listing requirements?
What is the significance of Kazia’s licensing agreement with Sovargen Co., Ltd?
Where can I find more information about Kazia Therapeutics?
